You are viewing: Egypt Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The Egypt Plasma Fractionation Market was valued at $121.9 Million in 2026 and projected to reach to $150.1 Million by 2031, representing a compound annual growth rate of CAGR 4.2%. Egypt's plasma fractionation market is positioned for steady growth driven by increasing healthcare expenditure and rising awareness of plasma-derived therapies.

Egypt Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Egypt Plasma Fractionation Market Trends and Insights

  • Egypt's healthcare sector is increasingly investing in advanced therapeutic solutions, with plasma-derived products playing a critical role in treating bleeding disorders, immunodeficiencies, and other life-threatening conditions.
  • The market in Egypt is driven by rising patient awareness, improved access to healthcare infrastructure, and growing demand for immunoglobulin and clotting factor therapies. The expansion of Egypt's plasma fractionation market reflects broader regional trends in the Middle East, where healthcare modernization and pharmaceutical innovation are accelerating.
  • Egypt's strategic position as a regional healthcare hub supports the adoption of plasma fractionation technologies and products.
  • Between 2026 and 2031, Egypt is expected to see steady growth fueled by government healthcare initiatives, increased hospital capacity, and partnerships with international plasma collection and fractionation organizations.
  • The market's moderate growth trajectory underscores Egypt's developing but expanding role in the global plasma fractionation supply chain..

Key Market Statistics

  • CAGR (2026-2031) CAGR 4.2%
  • Market Size, 2026 ~USD 121.9 Million
  • Forecast, 2031 ~USD 150.1 Million
  • Country Egypt

Egypt Plasma Fractionation Market Overview

Market Size & Growth :

Egypt's plasma fractionation market is valued at USD 121.9 million in 2026 and is projected to reach USD 150.1 million by 2031, with a steady CAGR of 4.2% over the forecast period.

Healthcare Investment Surge :

Egypt's healthcare sector is experiencing significant modernization, with increased government and private sector investments in advanced therapeutic solutions and plasma-derived products for critical medical applications.

Rising Disease Burden :

Growing prevalence of bleeding disorders, immunodeficiencies, and chronic diseases in Egypt is driving demand for plasma fractionation products as essential treatment options in hospitals and specialized clinics.

Regulatory & Infrastructure Development :

Egypt is strengthening its regulatory framework and healthcare infrastructure to support the adoption of plasma fractionation therapies, creating opportunities for market expansion and product accessibility.

Egypt Plasma Fractionation Market Dynamics

  • The country's expanding middle class and improved access to specialized medical facilities are creating favorable conditions for market penetration.
  • Government initiatives to enhance healthcare quality and the growing prevalence of conditions requiring plasma fractionation products are key growth catalysts. The forecast period through 2031 will see gradual market expansion as Egyptian healthcare providers invest in advanced treatment options.
  • However, growth remains moderate compared to global rates, reflecting challenges such as healthcare infrastructure limitations and cost considerations.
  • Strategic partnerships between local distributors and international manufacturers will be crucial for market development and ensuring product availability across Egypt's healthcare system..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • Egypt's plasma fractionation market is valued at USD 121.9 million in 2026 and will reach USD 150.1 million by 2031, growing at a 4.2% CAGR.
      • Egypt's healthcare modernization and increased investment in therapeutic biologics are driving demand for plasma-derived immunoglobulins and clotting factors.
      • Egypt's position as a regional healthcare hub in the Middle East supports market expansion through improved infrastructure and international partnerships.
      • Egypt's plasma fractionation market growth is supported by rising patient awareness, government healthcare initiatives, and expanding hospital capacity through 2031.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      Egypt Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Pharmaceutical & Biotech Companies : Manufacturers and distributors of plasma fractionation products need Egypt-specific market data to develop localized go-to-market strategies, pricing models, and distribution partnerships.
      • Healthcare Providers & Hospital Networks : Egyptian hospitals and clinics require market insights to make informed procurement decisions, understand treatment trends, and optimize inventory management for plasma-derived therapies.
      • Investment & Private Equity Firms : Investors evaluating opportunities in Egypt's healthcare sector need detailed market analysis to assess growth potential, competitive positioning, and return on investment in plasma fractionation.
      • Government & Healthcare Policy Makers : Egyptian health authorities and policymakers use market data to inform healthcare policy, budget allocation, and strategic initiatives for improving access to plasma fractionation treatments.
      • Medical Device & Diagnostic Companies : Suppliers of complementary products and services need Egypt market intelligence to identify cross-selling opportunities and develop integrated solutions for plasma fractionation applications.

      Reasons to Buy this Report

      • Market-Specific Sizing & Forecasts : Access precise market valuations for Egypt (USD 121.9M in 2026, USD 150.1M in 2031) with detailed CAGR analysis to support accurate business planning and investment decisions.
      • Competitive Landscape Intelligence : Understand Egypt-specific competitive dynamics, key players, market share distribution, and strategic positioning to identify partnership and expansion opportunities in this emerging market.
      • Regulatory & Reimbursement Insights : Gain comprehensive knowledge of Egypt's healthcare regulations, reimbursement policies, and compliance requirements specific to plasma fractionation products for market entry strategies.
      • Disease Prevalence & Patient Insights : Analyze Egypt-specific epidemiological data on bleeding disorders, immunodeficiencies, and other conditions driving plasma fractionation demand to tailor product strategies effectively.
      • Growth Opportunity Identification : Identify high-potential segments, emerging therapeutic areas, and geographic hotspots within Egypt to prioritize resource allocation and maximize market penetration.

      Frequently asked questions

      What is the current size of Egypt's plasma fractionation market?

      Egypt's plasma fractionation market is estimated at USD 121.9 million in 2026.

      What is the projected market size for Egypt's plasma fractionation sector by 2031?

      Egypt's plasma fractionation market is projected to reach USD 150.1 million by 2031.

      What is the CAGR for Egypt's plasma fractionation market from 2026 to 2031?

      Egypt's plasma fractionation market is expected to grow at a compound annual growth rate (CAGR) of 4.2% between 2026 and 2031.

      What are the primary drivers of growth in Egypt's plasma fractionation market?

      Key growth drivers in Egypt include rising patient awareness, improved healthcare infrastructure, government healthcare initiatives, and increased demand for immunoglobulin and clotting factor therapies.

      How does Egypt's plasma fractionation market compare to the global market?

      Egypt's plasma fractionation market grows at 4.2% CAGR, which is slower than the global CAGR of 7.6%, reflecting Egypt's developing market maturity within the Middle East region.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status